Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435842 | 1.00 | SLC6A4 (0.44) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2434409 | 0.90 | SLC6A4 (0.45) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2434408 | 0.90 | SLC6A4 (0.45) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2435071 | 0.82 | SLC6A4 (0.48) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2433062 | 0.82 | SLC6A4 (0.48) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL20953933 | 0.82 | SLC6A4 (0.48) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2433059 | 0.82 | SLC6A4 (0.48) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2435068 | 0.82 | SLC6A4 (0.48) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2437392 | 0.81 | SLC6A4 (0.50) | SLC6A4DRD4DRD2HPGDCYP1A2 | |
| SCHEMBL2436544 | 0.81 | POLB (0.49) | SLC6A4DRD4DRD2HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | claimed |
| WO-2010011302-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-01-28 | — | — | WO | claimed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010011302-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | SLC6A4 670/4885DRD4 3036/4885DRD2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.